Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
10.3350/cmh.2016.22.1.160
- Author:
Jung Min LEE
1
;
Byoung Kuk JANG
;
Yoo Jin LEE
;
Wang Yong CHOI
;
Sei Myong CHOI
;
Woo Jin CHUNG
;
Jae Seok HWANG
;
Koo Jeong KANG
;
Young Hwan KIM
;
Anil Kumar CHAUHAN
;
Soo Young PARK
;
Won Young TAK
;
Young Oh KWEON
;
Byung Seok KIM
;
Chang Hyeong LEE
Author Information
1. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. jangha106@dsmc.or.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Hepatocellular carcinoma;
Portal vein tumor thrombosis;
Transarterial chemoembolization;
Hepatic resection;
Sorafenib
- MeSH:
Adult;
Aged;
Antineoplastic Agents/*therapeutic use;
Carcinoma, Hepatocellular/complications/drug therapy/*therapy;
Chemoembolization, Therapeutic;
Combined Modality Therapy;
Female;
Follow-Up Studies;
Humans;
Liver Neoplasms/complications/drug therapy/*therapy;
Male;
Middle Aged;
Niacinamide/*analogs & derivatives/therapeutic use;
Phenylurea Compounds/*therapeutic use;
Portal Vein;
Proportional Hazards Models;
Retrospective Studies;
Severity of Illness Index;
Survival Rate;
Treatment Outcome;
Venous Thrombosis/*complications
- From:Clinical and Molecular Hepatology
2016;22(1):160-167
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial. We compared the outcomes of hepatic resection (HR), transarterial chemoembolization (TACE), and sorafenib therapy as treatments for HCC with PVTT. METHODS: Patients diagnosed as HCC with PVTT between January 2000 and December 2011 who received treatment with sorafenib, HR, or TACE were included. Patients with main PVTT, superior mesenteric vein tumor thrombosis, or Child-Turcotte-Pugh (CTP) class C were excluded. The records of 172 patients were analyzed retrospectively. HR, TACE, and sorafenib treatment were performed is 40, 80, and 52 patients respectively. PVTT was classified as either involving the segmental branch (type I) or extending to involve the right or left portal vein (type II). RESULTS: The median survival time was significantly longer in the HR group (19.9 months) than in the TACE and sorafenib groups (6.6 and 6.2 months, respectively; both p<0.001), and did not differ significantly between the latter two groups (p=0.698). Among patients with CTP class A, type I PVTT or unilobar-involved HCC, the median survival time was longer in the HR group than in the TACE and sorafenib groups (p=0.006). In univariate analyses, the initial treatment method, tumor size, PVTT type, involved lobe, CTP class, and presence of cirrhosis or ascites were correlated with overall survival. The significant prognostic factors for overall survival in Cox proportional-hazards regression analysis were initial treatment method (HR vs. TACE: hazard ratio=1.750, p=0.036; HR vs. sorafenib: hazard ratio=2.262, p=0.006), involved lobe (hazard ratio=1.705, p=0.008), PVTT type (hazard ratio=1.617, p=0.013), and CTP class (hazard ratio=1.712, p=0.012). CONCLUSIONS: Compared with TACE or sorafenib, HR may prolong the survival of patients with HCC in cases of CTP class A, type I PVTT or unilobar-involved HCC.
